Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics Inc (VVOS) provides innovative solutions for sleep-disordered breathing through its proprietary oral appliance therapy and integrated clinical protocols. This news hub offers investors and healthcare professionals direct access to official announcements, financial disclosures, and progress updates on the company's non-invasive treatment alternatives for obstructive sleep apnea.
Our curated collection features regulatory filings, partnership announcements, clinical trial updates, and technology developments. Users will find timely information about the Vivos System implementation, insurance coverage expansions, and research collaborations within the sleep medicine field.
The page organizes content by key categories including quarterly earnings reports, FDA communications, provider network growth, and peer-reviewed study publications. Each update maintains factual accuracy while highlighting the company's position in the $7 billion sleep apnea treatment market.
Bookmark this page for streamlined tracking of Vivos' progress in commercializing its oral appliance technology and expanding its licensed provider network. Check regularly for new developments in patient outcomes data and healthcare provider adoption rates across North America.
Vivos Therapeutics (NASDAQ: VVOS) announced groundbreaking results from a multicenter clinical trial for their DNA (Daytime-Nighttime Appliance®) device in treating pediatric obstructive sleep apnea (OSA). Published in the European Journal of Pediatrics, the study demonstrated significant efficacy with 77% of participants achieving at least 50% reduction in OSA severity, and 93% improvement rate in severe cases.
The trial revealed an average 67.8% increase in airway volume and 17% complete OSA resolution. This non-surgical alternative challenges the current standard adenotonsillectomy surgery, which is only effective in 20-40% of cases. The DNA appliance, part of Vivos' C.A.R.E. line, addresses a critical need as up to 20.4% of U.S. children suffer from OSA, with 90% remaining undiagnosed.
Vivos Therapeutics (NASDAQ:VVOS), a medical device company focused on sleep-related breathing disorders, reported Q2 2025 financial results marked by a strategic pivot in their business model. The company completed the acquisition of The Sleep Center of Nevada (SCN), generating approximately $500,000 in diagnostic sleep testing revenue in just 20 days.
Q2 2025 financial highlights include revenue of $3.8 million (down from $4.1M in Q2 2024), gross profit of $2.1 million with a 55% margin, and increased operating expenses of $7.0 million. The company ended the quarter with $4.4 million in cash. Additionally, Vivos entered into its first management agreement with MISleep Solutions LLC in Michigan, demonstrating progress in their updated sleep practice management model.
Vivos Therapeutics (NASDAQ:VVOS), a medical device and technology company focused on sleep-related breathing disorders treatment, has scheduled its Q2 2025 financial results release for August 19, 2025, after market close.
The company will host a conference call at 5:00 PM ET to discuss the results and provide updates on recent milestones. Investors can access the call via phone or webcast, with replay available until September 2, 2025.
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on treating obstructive sleep apnea (OSA), has announced two strategic executive appointments to support its expansion plans. Michael E. Bruhn joins as Executive Vice President of Business Operations Integration, while Dr. Terry Jones becomes Senior Vice President of Human Resources.
Bruhn, formerly EVP and COO at the United States Institute of Peace, will focus on expanding Vivos' operations in the Eastern United States and managing acquisitions integration, including the recent Sleep Center of Nevada acquisition. Dr. Jones, with over 20 years of leadership experience across federal agencies and private sector, will lead human resources strategy to support the company's growth phase.
Both executives will report directly to CEO R. Kirk Huntsman as Vivos implements its new business model focused on sleep testing centers and direct patient treatment operations.
Vivos Therapeutics (NASDAQ: VVOS) has achieved a significant milestone as its VidaSleep™ oral appliance received approval from the Centers for Medicare & Medicaid Services (CMS) for treating mild to moderate obstructive sleep apnea (OSA) and snoring in adults.
The VidaSleep™ device, featuring Vivos' patented and FDA-cleared Unilateral Bite Block technology, joins the company's mmRNA® device on the PDAC list of covered oral appliances. This dual-PDAC approval makes Vivos the only company with two Medicare-covered oral appliances, expanding access to millions of Medicare beneficiaries.
With an estimated 80 million Americans affected by OSA and over 80% of cases undiagnosed, Vivos is targeting the $36 billion sleep therapy market. The VidaSleep™ device is designed to offer a cost-effective solution without compromising efficacy, maintaining strong gross margins while expanding accessibility through Medicare and commercial insurance networks.
Vivos Therapeutics (NASDAQ: VVOS) announced the publication of groundbreaking clinical trial results in the European Journal of Pediatrics, demonstrating the effectiveness of their Daytime-Nighttime Appliance (DNA) in treating pediatric obstructive sleep apnea (OSA). The study showed 79% of patients experienced OSA improvement, with 61.7% improving by 50% or more.
The trial results validate Vivos' FDA 510(k) clearance received in September 2024 for treating moderate to severe OSA in children. Notably, 93% of children with severe OSA saw symptoms decrease by at least 50%. The DNA device presents a non-surgical alternative to adenotonsillectomy, which has a 68% symptom relapse rate within three years.
Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company focused on sleep-related breathing disorders treatments, has scheduled its first quarter 2025 financial results release for May 15, 2025, after market close. The company will host a conference call at 5:00 PM ET on the same day to discuss results and recent developments.
Investors can join via phone at (800) 717-1738 (US) or (646) 307-1865 (International). A replay will be available until May 29, 2025, accessible at (844) 512-2921 (US) or (412) 317-6671 (International) with passcode 1124460. A live webcast will be available on Vivos' website with 30-day replay access.
Vivos Therapeutics (NASDAQ: VVOS) has signed a definitive agreement to acquire The Sleep Center of Nevada (SCN), the largest sleep center operator in Nevada, for up to $9 million. The deal includes $6 million in cash, $1.5 million in Vivos common stock at closing, and potential additional $1.5 million in stock tied to performance milestones.
SCN, founded in 2008, serves approximately 3,000 new patients monthly and has generated high seven-figure annual net revenues. The center operates seven locations with nearly 50 beds for overnight sleep testing. About 90% of SCN patients test positive for OSA, with 95% typically referred for CPAP, traditional oral devices, or surgical options.
The acquisition, expected to close in Q2 or Q3 2025, aligns with Vivos' new marketing and distribution model following its June 2024 alliance with Rebis Health. The company aims to expand its FDA-cleared oral appliance treatments for OSA directly to patients seeking alternatives to CPAP or surgery.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
